All articles by Miranda Mclaren

Peptides in the pipeline: How companies are overcoming the early-stage challenges

Much larger than traditional small molecule drugs, peptides enable rapid tissue penetration while retaining the selectivity and potency of a…
Extracellular vesicles: The next frontier in regenerative medicine and drug delivery?

Extracellular vesicles (EVs) are tiny, membrane-bound particles released by every cell type studied to date. Though small, they carry a…
Navigating uncertainty and building resilient supply chains: The case for US-based CDMO partnerships

Choosing to onshore pharmaceutical manufacturing by partnering with a US-based contract development and manufacturing organization (CDMO) can offer advantages for…
Dermatology Trials by the Numbers: Key Trends and Benchmarks for 2026

Dermatology - spanning chronic inflammatory disease, infection, wound healing, pigment disorders, hair loss and rare genetic conditions - is nothing…
Doubling down on efficacy: Exploring the potential of dual-payload ADCs

Chemotherapy has been our main weapon against late-stage cancers for decades, bringing with it wide-ranging side effects caused by the…

Potency assays in cell therapies: A look behind the challenges

Dr. Scott Jones has spent more than 35 years advancing assay development and currently leads BioBridge Global’s R&D department. His…
Bile acid modulators in discovery: Identifying cholestasis candidates with the best chance of success

Disrupted bile flow, or cholestasis, is a key feature of various chronic liver diseases such as primary biliary cholangitis (PBC)…
Bio-based plastics for biopharma: How is parenteral packaging adopting eco-design?

In a parenteral packaging world often dominated by discussion of vials, stoppers, and pre-filled syringes, flip caps rarely take centre…
Aseptic filling of unstable drug products: How to protect sensitive drugs during the fill finish process

This article explores the typical fill-finish process, the potential impact on unstable drug products, and best practices to protect these…
The rise of large-volume injectors: Patient-centric innovation in biologics delivery

For decades, intravenous (IV) infusions in clinical settings were the standard for therapies such as monoclonal antibodies. Today, advances in…

Sections